---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007081"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:12:39.816452+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Atea ends 2025 with $301.8M cash; Phase 3 HCV data due mid-2026; HEV program advancing

## Summary
- Cash and investments $301.8M at Dec 31, 2025; cash runway expected through 2027.
- Phase 3 HCV C-BEYOND topline results mid-2026; C-FORWARD results year-end 2026.
- HEV Phase 1 study for AT-587 planned mid-2026; preclinical shows potent nanomolar anti-HEV activity.
- Market survey of 153 top DAA prescribers supports need for new HCV regimen; global HCV market ~$3B net sales annually.
- Atea will evaluate strategic transactions and global commercialization options to maximize reach.

## SEC filing metadata
- accession: 0001193125-26-007081
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312526007081/0001193125-26-007081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312526007081/d800383d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007081
- JSON: https://secwatch.observer/filing/0001193125-26-007081.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.